Eli Lilly and Company: Ovarian Neoplasms trials

The registry lists 29 Ovarian Neoplasms studies with Eli Lilly and Company as lead sponsor. 6 are open to participants now and 12 have results posted.

Phase 1 10Phase 2 17Phase 3 3Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of LY4336619 in Adult Participants With Advanced Solid TumorsNot yet recruitingNCT07928258Phase 1
• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingNCT07213804Phase 3
• A Study of LY4337713 in Participants With FAP-Positive Solid TumorsRecruitingNCT07213791Phase 1
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Phase 1
• A Study of Sofe-M in Participants With Selected Advanced Solid TumorsRecruitingNCT06400472Phase 1
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2
• A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian CancerCompletedNCT03414047Phase 2Results posted
• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results posted
• A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and NeckCompletedNCT01059643Phase 2Results posted
• A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian CancerCompletedNCT00913835Phase 2Results posted
• Study of Ramucirumab in Ovarian CancerCompletedNCT00721162Phase 2Results posted
• Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal CancerCompletedNCT00489359Phase 1/2Results posted
• A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal CancerCompletedNCT00461786Phase 2Results posted
• A Study of Chemotherapy Treatment for Patients With Ovarian CancerCompletedNCT00428610Phase 2Results posted
• Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal CancerCompletedNCT00420381Phase 2Results posted
• Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")CompletedNCT00391118Phase 2Results posted
• An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior ChemotherapyCompletedNCT00191646Phase 3Results posted
• Gemcitabine in Ovarian CancerCompletedNCT00191334Phase 2Results posted
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
• A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
• Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Active, not recruitingNCT04956640Phase 1/2
• An Expanded Access Program for AM0010 (Pegilodecakin)No longer availableNCT03554434
• A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.CompletedNCT00191607Phase 3
• A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue TreatmentCompletedNCT00190697Phase 4
• Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based ChemotherapyCompletedNCT00109096Phase 2
• A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal CarcinomaTerminatedNCT00082212Phase 2
• Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube CancerCompletedNCT00063401Phase 2
• Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal CancerTerminatedNCT00055432Phase 2
• Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal CancerCompletedNCT00003670Phase 2